The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of neoadjuvant chemotherapy with fluorouracil, leucovorin, oxaliplatin and docetaxel for resectable esophageal squamous cell carcinoma.
 
Shun Yamamoto
Honoraria - Bristol-Myers Squibb; MSD K.K; Ono Pharmaceutical; Taiho Oncology
Consulting or Advisory Role - HOKUTO; Ono Pharmaceutical
Expert Testimony - HOKUTO
 
Satoru Matsuda
Honoraria - Chugai Pharma; Covidien/Medtronic; Daiichi Sankyo/Lilly; Ethicon; MSD; Olympus Medical Systems; Ono Pharmaceutical
 
Shota Fukuoka
No Relationships to Disclose
 
Takahiro Tsushima
Honoraria - Bristol-Myers Squibb Japan; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
 
Akinori Watanabe
No Relationships to Disclose
 
Shigenori Kadowaki
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Merck KGaA; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly (Inst); MSD (Inst); Nobelpharma (Inst); Ono Pharmaceutical (Inst)
 
Hiroya Takeuchi
Honoraria - Bristol-Myers Squibb Japan; Daiichi Sankyo/Astra Zeneca; EA Pharma; Intuitive Surgical; Johnson & Johnson/MedTech; Kaken Pharmaceutical; Medicon; Medtronic; Miyarisan pharmaceutical; MSD K.K; Nihonkayaku; Novartis; Olympus Medical Systems; Ono Pharmaceutical; Otsuka; Sysmex; Taiho Pharmaceutical; Tsumura & Co.
Research Funding - Chugai Pharma (Inst); Kaken Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Tanabe Mitsubishi Pharmaceutical (Inst)
 
Ayumu Hosokawa
Honoraria - Astellas Pharma; AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly; MSD; Nihon Zouki; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Chugai Pharma (Inst)
 
Yohei Kubota
No Relationships to Disclose
 
Takako Yoshii
Honoraria - Bristol-Myers Squibb Japan; MSD; Ono Pharmaceutical
 
Ken Kato
Honoraria - BMS; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - Bayer; BeiGene; MSD; Oncolys BioPharma; Ono Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb Japan; MSD; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Chugai Pharma (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)
 
Hiroki Osumi
Honoraria - Bristol-Myers Squibb; Guardant Health; Lilly Japan; Merck; MSD K.K; Taiho Pharmaceutical
 
Masahiro Niihara
No Relationships to Disclose
 
Tetsuya Abe
No Relationships to Disclose
 
Ryo Takemura
No Relationships to Disclose
 
Kenro Hirata
Honoraria - Bristol-Myers Squibb Company; Eli Lilly Japan K.K.; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Ono Pharmaceutical; Taiho Pharmaceutical
 
Yasuo Hamamoto
Consulting or Advisory Role - Chugai Pharma; Dainippon Sumitomo Pharma
Research Funding - Bristol-Myers Squibb Japan; Lilly Japan; MSD Oncology; Ono Pharmaceutical
 
Hirofumi Kawakubo
No Relationships to Disclose
 
Yuko Kitagawa
Honoraria - Asahi Kasei; ASKA Pharmaceutical Co., Ltd.; Astellas Pharma; AstraZeneca Japan; Bristol-Myers Squibb K.K.; Chugai Foundation for Innovative Drug Discovery Science; Chugai Pharma; DAIICHI SANKYO COMPANY, LIMITED; EA Pharma; Eisai; Ethicon; Intuitive Surgical; Japan Lifeline Co.,Ltd.; Kaken Pharmaceutical; Kowa; Miyarisan pharmaceutical; MSD K.K.; Nippon Covidien; Nippon Kayaku; Olympus; Ono Pharmaceutical; Otsuka; Shionogi; Smart Hospital Inc.; Sysmex; T-PEC CORPORATION; Taiho Pharmaceutical; Takeda; Toray Industries; TSUMURA & CO.
Consulting or Advisory Role - Bristol-Myers Squibb K.K.; Ono Pharmaceutical
Research Funding - Asahi Kasei (Inst); Chugai Pharma (Inst); Eisai (Inst); Kaken Pharmaceutical (Inst); Kowa (Inst); Kyouwa Hakkou Kirin Co., Ltd. (Inst); Nippon Covidien (Inst); Otsuka (Inst); Otsuka (Inst); Sumitomo Pharma Co., Ltd. (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Teijin Pharma (Inst); TSUMURA & CO. (Inst)